Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Midface Volume Deficit Clinical Trial

Official title:

A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03097783
• Other study ID #: 43CH1507
• Status: Completed
• Phase: N/A
• Start date: April 26, 2017
• Est. completion date: September 14, 2018

Study information

• Verified date: June 2021
• Source: Galderma R&D
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, multi-center, evaluator-blinded, no-treatment controlled study to evaluate the efficacy and safety of Restylane Perlane Lidocaine for correction of Midface Volume Deficit and/or Midface Contour Deficiency.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 169
• Est. completion date: September 14, 2018
• Est. primary completion date: March 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent

2. Men or women aged 18 years of age or older of Chinese origin

3. Subjects willing to abstain from any other facial plastic surgical or cosmetic procedures below the level of the lower orbital rim for the duration of the study

4. Subjects seeking augmentation therapy for the midface

5. MMVS score of 2, 3 or 4 on each side of the face as assessed by the blinded evaluator

Exclusion Criteria:

1. Known/previous allergy or hypersensitivity to any injectable HA gel/local anaesthetics, e.g.lidocaine or other amide-type anaesthetics.

2. Previous surgery or tattoo in the area to be treated

3. Previous tissue augmentation therapy or contouring with any permanent (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or permanent implant below the level of the lower orbital rim.

4. Previous use of any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy below the level of the lower orbital rim or neurotoxin within 12 months before treatment.

5. Scars or deformities, active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema, rosacea, acne psoriasis and herpes zoster near or in the area to be treated.

6. Other condition preventing the subject from entering the study in the Investigator's opinion.

Related Conditions & MeSH terms

• Midface Volume Deficit

Intervention

Device:
• Restylane Perlane Lidocaine
Intradermal injection

Locations

Country	Name	City	State
China	Q-Med AB	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Galderma R&D

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale	The primary objective is to demonstrate superiority of Perlane-Lido relative to no-treatment in the treatment of Midface volume Deficit and/or Midface Contour Deficiency by comparing the percent responders, defined by at least 1 point improvement from baseline on the MMVS on both sides of the face, as measured by blinded evaluator at 6 months.; Medicis Midface Volume Scale (MMVS) is a 4-grade scale assesses the fullness of the midface from Fairly Full (1) to Substantial Loss of Fullness (4) as described below. The blinded evaluator and treating investigator will rate the subject's right and left midface for severity of volume deficiency using the MMVS at all applicable study visits.; Fairly full midface; Mild loss of fullness in midface area; Moderate loss of fullness with slight hollowing below malar prominence; Substantial loss of fullness in the midface area, clearly apparent hollowing below malar prominence	6 month